Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:AUPNYSE:BHCNASDAQ:CARANYSE:NVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsBHCBausch Health Companies$5.91-1.3%$4.87$3.96▼$9.85$2.19B0.282.61 million shs5.11 million shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4124,800 shs237,144 shsNVONovo Nordisk A/S$77.02-3.5%$67.61$57.00▼$148.15$345.62B0.667.02 million shs8.14 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BHCBausch Health Companies-1.83%+21.00%+26.31%-15.70%-6.57%CARACara Therapeutics0.00%0.00%0.00%+2.31%+26.67%NVONovo Nordisk A/S-3.61%+2.07%+19.69%-4.86%-45.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABHCBausch Health Companies4.5713 of 5 stars2.92.00.04.04.23.31.9CARACara Therapeutics0.2835 of 5 stars0.00.00.04.20.60.80.0NVONovo Nordisk A/S4.6352 of 5 stars4.13.02.50.02.10.04.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPAurinia Pharmaceuticals 0.00N/AN/AN/ABHCBausch Health Companies 1.86Reduce$7.4225.60% UpsideCARACara Therapeutics 0.00N/AN/AN/ANVONovo Nordisk A/S 2.27Hold$112.0045.42% UpsideCurrent Analyst Ratings BreakdownLatest NVO, AUP, BHC, and CARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.004/28/2025NVONovo Nordisk A/SHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/25/2025NVONovo Nordisk A/SDbs BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSell4/17/2025NVONovo Nordisk A/SGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/17/2025NVONovo Nordisk A/SBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$105.00 ➝ $64.004/15/2025NVONovo Nordisk A/SBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy ➝ Underperform4/7/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform$9.00 ➝ $8.50(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPAurinia PharmaceuticalsC$57.59M0.00N/A6.75C$2.59 per share0.00BHCBausch Health Companies$9.73B0.22$6.28 per share0.94($0.89) per share-6.63CARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00NVONovo Nordisk A/S$303.14B1.14$3.57 per share21.57$4.64 per share16.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPAurinia PharmaceuticalsN/A-C$1.48N/AN/AN/AN/AN/AN/AN/ABHCBausch Health Companies-$46M-$0.11N/A1.270.37-0.48%-577.82%5.24%7/30/2025 (Estimated)CARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ANVONovo Nordisk A/S$14.64B$3.3823.4116.530.9034.81%84.68%26.29%8/6/2025 (Estimated)Latest NVO, AUP, BHC, and CARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025NVONovo Nordisk A/S$0.92$0.92N/A$0.92N/A$11.87 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/ABHCBausch Health CompaniesN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/ANVONovo Nordisk A/S$1.632.12%N/A48.22%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPAurinia Pharmaceuticals2.6911.9311.02BHCBausch Health CompaniesN/A0.860.62CARACara TherapeuticsN/A4.774.71NVONovo Nordisk A/S0.620.740.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPAurinia PharmaceuticalsN/ABHCBausch Health Companies78.65%CARACara Therapeutics44.66%NVONovo Nordisk A/S11.54%Insider OwnershipCompanyInsider OwnershipAUPAurinia PharmaceuticalsN/ABHCBausch Health Companies8.05%CARACara Therapeutics3.10%NVONovo Nordisk A/S0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPAurinia Pharmaceuticals300128.40 millionN/ANot OptionableBHCBausch Health Companies19,900370.08 million338.06 millionOptionableCARACara Therapeutics804.57 million4.43 millionOptionableNVONovo Nordisk A/S54,4004.49 billion4.48 billionOptionableNVO, AUP, BHC, and CARA HeadlinesRecent News About These CompaniesNovo Nordisk: An Elite Company That Prints MoneyJune 16 at 11:28 PM | seekingalpha.comWhy Novo Nordisk Stock Sank by Nearly 4% TodayJune 16 at 7:03 PM | fool.comNovo Nordisk A/S (NYSE:NVO) Shares Down 3.1% - Here's What HappenedJune 16 at 3:51 PM | marketbeat.comNovo Nordisk Stock Rises 6% in a Week: What Should Investors Do?June 16 at 1:36 PM | zacks.comNovo Nordisk A/S (NYSE:NVO) Shares Gap Down - What's Next?June 16 at 1:21 PM | marketbeat.comOzempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard SaynorJune 16 at 12:26 PM | benzinga.comFNY Investment Advisers LLC Makes New $623,000 Investment in Novo Nordisk A/S (NYSE:NVO)June 16 at 7:45 AM | marketbeat.comShikiar Asset Management Inc. Sells 90,399 Shares of Novo Nordisk A/S (NYSE:NVO)June 16 at 7:26 AM | marketbeat.comSolstein Capital LLC Trims Stake in Novo Nordisk A/S (NYSE:NVO)June 16 at 6:38 AM | marketbeat.comBrown Miller Wealth Management LLC Has $791,000 Position in Novo Nordisk A/S (NYSE:NVO)June 16 at 6:37 AM | marketbeat.comThe story of how Novo Nordisk will lose billions because it didn't pay a couple of hundred dollarsJune 16 at 5:03 AM | marketwatch.comNovo Nordisk: The Strength To Withstand ChallengesJune 16 at 5:03 AM | seekingalpha.comNovo Nordisk A/S (NYSE:NVO) Shares Acquired by North Star Investment Management Corp.June 16 at 5:00 AM | marketbeat.comJim Cramer on Novo Nordisk: “We’re Not Novo People”June 15 at 7:47 PM | msn.comBernstein Keeps a Hold on Novo Nordisk (NVO), Sets a DKK620 Price TargetJune 15 at 7:47 PM | msn.comRitholtz Wealth Management Trims Stock Position in Novo Nordisk A/S (NYSE:NVO)June 15 at 6:57 AM | marketbeat.comWealthcare Advisory Partners LLC Sells 21,139 Shares of Novo Nordisk A/S (NYSE:NVO)June 15 at 3:56 AM | marketbeat.comNovo Nordisk A/S (NYSE:NVO) Shares Sold by Yousif Capital Management LLCJune 15 at 3:56 AM | marketbeat.comNovo Nordisk A/S (NYSE:NVO) Upgraded to "Buy" at Wall Street ZenJune 15 at 3:51 AM | americanbankingnews.comDover Advisors LLC Purchases Shares of 7,154 Novo Nordisk A/S (NYSE:NVO)June 14 at 8:39 AM | marketbeat.comAzzad Asset Management Inc. ADV Buys New Shares in Novo Nordisk A/S (NYSE:NVO)June 14 at 6:36 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?With Novo Nordisk's CEO Out, Wall Street Wants an American LeaderBy Leo Miller | June 7, 2025View With Novo Nordisk's CEO Out, Wall Street Wants an American LeaderNVO, AUP, BHC, and CARA Company DescriptionsAurinia Pharmaceuticals TSE:AUPAurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Bausch Health Companies NYSE:BHC$5.90 -0.08 (-1.25%) Closing price 06/16/2025 03:59 PM EasternExtended Trading$5.97 +0.06 (+1.10%) As of 04:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Novo Nordisk A/S NYSE:NVO$77.02 -2.81 (-3.52%) Closing price 06/16/2025 03:59 PM EasternExtended Trading$76.43 -0.59 (-0.76%) As of 04:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
